|
| Author | Study design | Population | Intervention group and protocol | Control | Outcome |
|
| Gautret et al., 2020 [8] | Open-label nonrandomized clinical trial | Age > 12 | HCQ: 20
Protocol: 200 mg tid/10 days | Non-HCQ: 16 | Viral cure on day 6 (14/20 vs. 2/16): HCQ group 8/14 and HCQ + AZ 6/6. Mortality: 1/14 vs. none; ICU admission: 3/14 vs. none. Adverse effects: 1/14 (nausea) vs. none |
| Barbosa Espe et al., 2020 [32] | | Age > 18 | HCQ: 412
Protocol: 800 mg/on day 1, 400 mg/6 days and AZ 500 mg/day/5 days | Non-HCQ: 224 | Need for hospitalization: HCQ + AZ, 8/412 vs. 12/224 |
| Tang et al., 2020 [20] | | Age ≥ 18 | HCQ group: 75
Protocol: 1.2 gd LD/d/3 days, and then, 800 mg/d for 2-3 weeks | Non-HCQ: 75 | Viral cure on day 28: 53/75 vs. 56/75; adverse effect: 21/75 vs. 7/80 |
| Jun et al., 2020 [21] | | Age ≥ 18 | HCQ: 15
Protocol: HCQ 400 mg qod 5/days | Non-HCQ: 15 | Viral cure after day 7: 13 vs. 14; adverse effects: 4/15 vs. 3/15 |
| Chen et al., 2020 [22] | | Age ≥ 18 | Non-HCQ: 15
Protocol: 400 mg/d/5 days | Non-HCQ group: 31 | Clinical deterioration: 2 vs. 9; progression to severe illness: 0 vs. 4 |
| Geleris et al., 2020 [4] | Prospective observational study | Adults | HCQ: 811 protocol: 600 mg bid day 1 and then 400 mg daily for a median of 5 days) | Non-HCQ: 562 | Mortality: HCQ, 157/811; non-HCQ, 75/565
Intubated: 154/811; non-HCQ, 26/565 |
| Rosenberg et al., 2020 [14] | Retrospective cohort | All patients | HCQ + AZ: 735
HCQ: 271
Protocol: not clear! | Non-HCQ + AZ: 221 | Mortality: HCQ + AZ: 189/735; HCQ: 54/271; none: 28/221
ICU admission: HCQ: 52, non-HCQ: 27; HCQ + AZ: 226/735
QTc prolongation: HCQ + AZ: 81; HCQ: 39; none: 15
Arrhythmia: HCQ + AZ: 150; HCQ:44; and none: 23
Cardiac arrest: HCQ + AZ:114; HCQ:37; none:13 |
| Mercuro et al., 2020 [33] | Retrospective cohort | | HCQ + AZ: 53 | Non-HCQ alone: 37 | QTc prolongation: HCQ + AZ: 11/53 and HCQ: 7/37 |
| Saleh et al., 2020 [26] | Prospective study | | HCQ + AZ: 119 | Non-HCQ: 191 | QTc prolongation: HCQ + AZ: 11/119 and HCQ: 7/191 |
| Mahévas et al., 2020 [13] | Comparative observational study | Age ≥ 18 years | HCQ: 84
Protocol: 600 mg within 48 hours of admission | Non-HCQ: 89 | Mortality: 9/84 vs. 8/89. ICU admission: 8/84 vs. 14/89 |
| Yu et al., 2020 [30] | Retrospective observational | Not specified | HCQ: 48
Protocol:200 mg bid/7–10 days | Non-HCQ: 520 | Mortality: 9/48 vs. 238/520 |
| Magagnoli et al., 2020 [31] | Retrospective observational | Not specified | HCQ: 97
HCQ + AZ: 113 | Non-HCQ: 158 | Mortality: HCQ: 27; HCQ + AZ: 25; no HCQ: 18. ICU admission/need for ventilation: HCQ: 12/90; HCQ + AZ: 7/101; no HCQ: 25/177 |
|
